Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka(Kindai University), Pasi A. Jänne(Harvard University), Kazuto Nishio(Kindai University Sakai Hospital), Yasuhito Fujisaka(Kindai University), Koji Takeda(NewYork–Presbyterian Hospital), Marileila Varella‐Garcia(University of Colorado Anschutz Medical Campus), Eugene Lifshits(Massachusetts General Hospital), Kreshnik Zejnullahu(Beth Israel Deaconess Medical Center), Jeffrey A. Engelman(Cancer Research Center), Massimo Roncalli(Fondazione Humanitas per la Ricerca), Toshio Shimizu(Wakayama Medical University), Takafumi Okabe(Dana-Farber Cancer Institute), Yong Gon Cho(University of Colorado Cancer Center), Ramesh A. Shivdasani(Harvard University), Jason Sun(Dana-Farber Cancer Institute), Taroh Satoh(Osaka University Hospital), Osamu Maenishi(Kindai University), Koichi Taira(Osaka City General Hospital), Andrew M. Rogers(Beth Israel Deaconess Medical Center), Isamu Okamoto(Kyushu University Hospital), John Souglakos(University of Crete), Masayuki Takeda(Kindai University), Annarita Destro(Izumi City General Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Masahiro Fukuoka(National Institute of Standards and Technology), Minoru Takada(Kindai University Hospital), Juliet Philips(Dana-Farber Cancer Institute), Kiyotaka Okuno(Kindai University), Federico Cappuzzo(Ospedale di Livorno), Jeffrey Swanson(Dana-Farber Cancer Institute), Dalia Ercan(Dana-Farber Cancer Institute)
Cited by 670
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k